Portal de Periódicos da CAPES

Lack of Evidence for an Effect of Lopinavir/Ritonavir on Tenofovir Renal Clearance

2008; Wiley; Volume: 84; Issue: 6 Linguagem: Inglês

10.1038/clpt.2008.140

1532-6535

Adrian S. Ray, Matthew Wright, GR Rhodes,

Metabolism and Genetic Disorders

Clinical Pharmacology & TherapeuticsVolume 84, Issue 6 p. 660-660 Letters to the Editor Lack of Evidence for an Effect of Lopinavir/Ritonavir on Tenofovir Renal Clearance AS Ray, Corresponding Author AS Ray [email protected] Department of Drug Metabolism, Gilead Sciences, Foster City, California, USASearch for more papers by this authorMR Wright, MR Wright Department of Drug Metabolism, Gilead Sciences, Foster City, California, USASearch for more papers by this authorGR Rhodes, GR Rhodes Department of Drug Metabolism, Gilead Sciences, Foster City, California, USASearch for more papers by this author AS Ray, Corresponding Author AS Ray [email protected] Department of Drug Metabolism, Gilead Sciences, Foster City, California, USASearch for more papers by this authorMR Wright, MR Wright Department of Drug Metabolism, Gilead Sciences, Foster City, California, USASearch for more papers by this authorGR Rhodes, GR Rhodes Department of Drug Metabolism, Gilead Sciences, Foster City, California, USASearch for more papers by this author First published: 09 July 2008 https://doi.org/10.1038/clpt.2008.140Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Kiser, J.J. et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin. Pharmacol. Ther. 83, 265–272 (2008). 10.1038/sj.clpt.6100269 CASPubMedWeb of Science®Google Scholar 2Ray, A.S. et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents Chemother. 50, 3297–3304 (2006). 10.1128/AAC.00251-06 CASPubMedWeb of Science®Google Scholar 3Cihlar, T. et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antiv. Ther. 12, 267–272 (2007). CASPubMedWeb of Science®Google Scholar 4Polli, J.W. et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16, 1206–1212 (1999). 10.1023/A:1018941328702 CASPubMedWeb of Science®Google Scholar 5Tong, L. et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob. Agents Chemother. 51, 3498–3504 (2007). 10.1128/AAC.00671-07 CASPubMedWeb of Science®Google Scholar Citing Literature Volume84, Issue6Adolescent PharmacologyDecember 2008Pages 660-660 ReferencesRelatedInformation